Cart
sales@molnova.com
BCL6 PROTAC 15
CAS No. ——
BCL6 PROTAC 15( —— )
Catalog No. M16949 CAS No. ——
BCL6 PROTAC 15 is a novel B-cell lymphoma 6 (BCL6) PROTAC, significantly degrade BCL6 in a number of DLBCL cell lines.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 100MG | Get Quote | Get Quote |
|
| 200MG | Get Quote | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameBCL6 PROTAC 15
-
NoteResearch use only, not for human use.
-
Brief DescriptionBCL6 PROTAC 15 is a novel B-cell lymphoma 6 (BCL6) PROTAC, significantly degrade BCL6 in a number of DLBCL cell lines.
-
DescriptionBCL6 PROTAC 15 is a novel B-cell lymphoma 6 (BCL6) PROTAC, significantly degrade BCL6 in a number of DLBCL cell lines, but neither BCL6 inhibition nor degradation selectively induces marked phenotypic response.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayPROTACs
-
TargetPROTAC
-
RecptorPROTAC
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number——
-
Formula Weight976.482
-
Molecular FormulaC47H58ClN9O12
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES——
-
Chemical Name4-((R)-25-chloro-41-methyl-42-oxo-41,42,43,44-tetrahydro-5,8-dioxa-3-aza-4(6,8)-quinolina-2(2,4)-pyrimidina-1(1,2)-piperazinacyclononaphane-14-yl)-N-(3-(2-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)ethoxy)ethoxy)propyl)-4-oxobutanamide compound with ethane (1:1)
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. McCoull W, et al. ACS Chem Biol. 2018 Oct 17. doi: 10.1021/acschembio.8b00698.
molnova catalog
related products
-
(S,R,S)-AHPC-PEG3-N3
(S,R,S)-AHPC-PEG3-N3 is a synthesized E3 ligase ligand-linker conjugate that incorporates the (S,R,S)-AHPC based VHL ligand and 3-unit PEG linker used in PROTAC technology. (S,R,S)-AHPC-PEG3-N3 is extracted from patent WO/2016/146985A1.
-
A1874
A1874 (A-1874) is a nutlin-based and BRD4-degrading PROTAC with DC50 of 32 nM (induce BRD4 degradation in cells).
-
PAC
PAC1 (Compound PAC1) is a novel PROTAC antibody conjugate, more potent estrogen receptor-alpha (ERα) degrader compared to PROTAC without antibody conjugation.
